Core Viewpoint - Zhuozheng Medical Holdings Limited is set to launch its IPO, aiming to raise over HKD 300 million, with a diverse base of cornerstone investors including notable tech companies and medical institutions [2][3][4]. Group 1: IPO Details - Zhuozheng Medical plans to issue 4,750,000 shares, with 475,000 shares available for public offering in Hong Kong and 4,275,000 shares for international offering [2]. - The IPO is scheduled to run from today until February 3, with the listing on the Hong Kong Stock Exchange planned for February 6, 2026, under the stock code "2677" [2]. Group 2: Investment and Partnerships - The cornerstone investors include prominent figures and companies such as He Xiaopeng from XPeng Motors, Minglue Technology, and leading third-party testing firm Kingmed, indicating strong industry confidence [2][3]. - Tencent is already the largest institutional investor in Zhuozheng Medical, holding approximately 20% of the shares, alongside other notable investors like Matrix Partners and Huafu Capital [4]. Group 3: Market Position and Strategy - Established in 2012, Zhuozheng Medical focuses on the mid-to-high-end medical service market, targeting affluent consumers who prefer personalized healthcare [4]. - According to Frost & Sullivan, Zhuozheng Medical ranks first and second in terms of covered cities and paid patient visits among private mid-to-high-end comprehensive medical service providers in China [4]. Group 4: Customer Engagement and Retention - Zhuozheng Medical has achieved high customer retention rates, with membership renewal rates increasing from 42% in 2022 to 67% in the first eight months of 2025, and patient return rates rising from 75.7% to 82.7% in the same period [5]. - The company employs a Costco-like business model, utilizing a membership system to enhance customer frequency and loyalty, resulting in an average of nearly four visits per customer in 2024 [6]. Group 5: Financial Performance - Zhuozheng Medical has demonstrated revenue growth from CNY 473 million in 2022 to CNY 959 million in 2024, with a compound annual growth rate (CAGR) of 42.2% [7]. - The gross profit increased significantly from CNY 44 million in 2022 to CNY 226 million in 2024, with a CAGR of 126.7% [8]. - The company achieved profitability in 2024, with an adjusted net profit of approximately CNY 10.45 million in the first eight months of 2025 [8]. Group 6: Future Plans - The net proceeds from the IPO will be primarily used to build a professional talent pool for medical AI applications, enhance existing medical facilities, and explore acquisition opportunities in first-tier and new first-tier cities [8].